ArticleMolecular neurobiology2025
IL17A Mediates Glycolysis-Dependent Primary Angiogenesis and Exacerbates Ischemic Stroke Injury.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ischemic stroke poses a significant threat due to its high mortality and disability rates, mainly because of the narrow therapeutic window associated with a complex inflammatory response process and blood brain barrier (BBB) disruption. Therefore, inhibiting the inflammatory response or restoring BBB integrity could potentially salvage brain tissue. Interleukin-17A (IL17A) is recognized as an initiator of inflammatory signaling and is implicated in the post-ischemic stroke inflammatory cascade. However, further exploration is needed to fully understand its underlying mechanisms. This study aims to investigate how IL17A as an inflammatory factor regulates angiogenesis to exacerbate BBB permeability and brain injury, thus shedding light on the potentially detrimental mechanism of IL17A in ischemic stroke. A mouse model of middle cerebral artery occlusion was established, with the experimental group the experimental group receiving intracerebral injections of recombinant murine IL17A. Neurobehavioral functions were assessed using Longa scoring, infarct volume was quantified via 2,3,5-triphenyltetrazolium chloride staining, and western blot analysis was conducted to evaluate the expression levels of proteins. Immunohistochemistry was employed to examine CD31, Claudin 5 and Iba-1 correlations, while tail vein injection of Evans Blue and IgG staining were utilized to assess BBB permeability. Transmission electron microscopy was employed to observe tight junction structures. Cellular experiments involved in bEnd.3 cells, ATP measurements using kits, and TUNEL staining to evaluate apoptosis. IL-17A promotes post-stroke defective angiogenesis, enhances inflammatory cell infiltration, and exacerbates cerebral infarction; Defective angiogenesis in the acute phase leads to increased matrix metalloproteinase secretion, TJ degradation, and enhanced BBB permeability; IL17A-induced angiogenesis relies on glycolysis for energy provision; Glycolysis preferentially fuels cellular self-rescue mechanisms over apoptotic pathways. IL17A facilitates dependent "defective angiogenesis" during the acute phase of MCAO, intensifying inflammatory cell infiltration, and BBB permeability by upregulating MMP-9 to degrade TJs, thereby exacerbating ischemic brain injury.
Indexed as
Identifiers
41288830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.